Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2133849 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL3669860 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL14191224 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL8320089 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL13646429 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL8037005 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL13630595 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL3793643 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL3793642 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL11894637 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008022006-A2 | ARYLALKOXYL HEPATITIS C VIRUS PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |